Abstract
In a limited subset of patients, dupilumab-induced hypereosinophilia is persistent. Two-month follow-up eosinophil count may predict long-lasting hypereosinophilia.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have